S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
Log in

NASDAQ:UMRX - Unum Therapeutics Stock Price, Forecast & News

$0.95
-0.03 (-3.06 %)
(As of 01/28/2020 04:00 PM ET)
Today's Range
$0.92
Now: $0.95
$1.01
50-Day Range
$0.51
MA: $0.79
$1.19
52-Week Range
$0.48
Now: $0.95
$4.87
Volume167,200 shs
Average Volume284,167 shs
Market Capitalization$29.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UMRX
CUSIPN/A
Phone617-945-5576

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.73 million
Book Value$2.01 per share

Profitability

Net Income$-34,530,000.00
Net Margins-388.07%

Miscellaneous

Employees56
Market Cap$29.13 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.


Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions

What is Unum Therapeutics' stock symbol?

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

How were Unum Therapeutics' earnings last quarter?

Unum Therapeutics Inc (NASDAQ:UMRX) issued its earnings results on Tuesday, November, 12th. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.07. The company had revenue of $1.02 million for the quarter, compared to analyst estimates of $4.41 million. Unum Therapeutics had a negative return on equity of 96.07% and a negative net margin of 388.07%. View Unum Therapeutics' Earnings History.

When is Unum Therapeutics' next earnings date?

Unum Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Unum Therapeutics.

What price target have analysts set for UMRX?

5 brokerages have issued 12-month target prices for Unum Therapeutics' shares. Their forecasts range from $3.00 to $18.00. On average, they expect Unum Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.

What is the consensus analysts' recommendation for Unum Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.

What are Wall Street analysts saying about Unum Therapeutics stock?

Here are some recent quotes from research analysts about Unum Therapeutics stock:
  • 1. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (11/9/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.0/share, as a 25x multiple of taxed and diluted $7.63 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.5/share (discounted cash flow analysis using a 18.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2019)

Has Unum Therapeutics been receiving favorable news coverage?

News coverage about UMRX stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Unum Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near term. View News Stories for Unum Therapeutics.

Are investors shorting Unum Therapeutics?

Unum Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 372,700 shares, a drop of 18.6% from the December 31st total of 457,600 shares. Based on an average daily trading volume, of 310,800 shares, the short-interest ratio is presently 1.2 days. Currently, 2.9% of the company's stock are short sold. View Unum Therapeutics' Current Options Chain.

Who are some of Unum Therapeutics' key competitors?

What other stocks do shareholders of Unum Therapeutics own?

Who are Unum Therapeutics' key executives?

Unum Therapeutics' management team includes the folowing people:
  • Dr. Charles Wilson, CEO, Pres & Director (Age 54)
  • Mr. Michael J. Vasconcelles, Chief Medical Officer (Age 55)
  • Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
  • Mr. John L. Green, VP of Fin. (Age 39)
  • Mr. Geoffrey Hodge, Chief Technical Officer & Sr. VP of Operations (Age 54)

When did Unum Therapeutics IPO?

(UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

How do I buy shares of Unum Therapeutics?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Unum Therapeutics' stock price today?

One share of UMRX stock can currently be purchased for approximately $0.95.

How big of a company is Unum Therapeutics?

Unum Therapeutics has a market capitalization of $29.13 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.

What is Unum Therapeutics' official website?

The official website for Unum Therapeutics is http://www.unumrx.com/.

How can I contact Unum Therapeutics?

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]


MarketBeat Community Rating for Unum Therapeutics (NASDAQ UMRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Unum Therapeutics and other stocks. Vote "Outperform" if you believe UMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel